Early market access pathways (EMAPs) have evolved rapidly over the recent years, with "adaptive pathways" being piloted in Europe, and the introduction of early conditional approval for regenerative / cell / gene therapy products in Japan. This research aims to provide an update on the early / accelerated access pathways in Europe and Japan, and to understand their impact on the reimbursement and pricing potentials for the products.
METHOD
European Medicine Agency (EMA) and market-specific websites on market authorisation and Health technology assessment (HTA) evaluations were assessed for updates on the early / accelerated access pathways. Reports from HTA bodies were analysed to understand the reimbursement implications of the products that underwent early / accelerated access pathways. Payers (2-3 per market in France, Germany, UK and Japan) were interviewed to validate and substantiate the findings from secondary research.
RESULTS

Overview
Early access pathways are present at the EMA level and also at country-specific levels in Europe and Japan.
Criteria for entering these early access pathways vary by scheme types. But essentially, they are all intended for innovative / promising new therapy, in therapy areas of high unmet needs, where the benefits of providing the new therapy early outweighs the risk of not having full data.
Even when the products are accepted to the early access pathways, formal standard HTA assessment is still required at the end of early access period, in order to gain full approval.
Part 1: EMA early access pathways
In Europe, conditional market authorization (CMA) from EMA forms a key backbone for "adaptive pathways" being piloted.
While the CMA provides early regulatory approval for new medicines in the disease areas of high unmet need, the downstream HTA assessment process at the country level has remained relatively unchanged. • In Germany, the CMA products with orphan status were reimbursed since benefit is assumed for orphan drugs under the AMNOG law; however, the CMA products without orphan status were generally not recommended by GBA due to failure to ascertain added benefit with less robust trial design and immature data 2 .
• In the UK, the products that received CMA from EMA were frequently rejected by NICE and SMC in the UK for reimbursement due to inability to demonstrate cost-effectiveness with limited data 3 . Early regulatory approval by EMA alone will not lead to true "early access", without coupled changes to the downstream HTA assessment and reimbursement decisions at the country level.
EARLY MARKET ACCESS PATHWAYS IN EUROPE AND JAPAN: CURRENT DEVELOPMENT AND IMPLICATIONS ON REIMBURSEMENT AND PRICING
There is a clear need to engage multiple stakeholders (EMA and country-specific HTA bodies) to ensure the full pathway is aligned at all stages that truly leads to "early access". Such need is recognized by EMA, and is reflected its new initiative of the adaptive pathway that is currently being piloted.
Part 2: Market-specific early access pathways in Europe
Market-specific early access pathways exist, which run independently from the CMA pathway by EMA. Therefore, a new product can apply for these market-specific early access pathways without having to have CMA from EMA first.
Some payers regard these market-specific early access pathways more highly than the EMA CMA, since the decision is made by the individual counties themselves, and also the acceptance to such schemes is perceived a recognition of innovative nature given innovation is one key criteria. • During ATU, the product is reimbursed, and the price is set by the manufacturer • After ATU, reimbursement is only continued if the product has acceptable SMR rating -There were a minority of cases, where the reimbursement was stopped after ATU, due to low SMR rating • The price is negotiated after ATU period, based on ASMR rating -If the price is lower than the price set by the manufacturer during the ATU period, then the manufacturer is required to pay back the differences In the UK, Early Access to Medicine Scheme (EAMS) was introduced in 2014 to provide early access to innovative therapies.
The scheme is still relatively new and only very few products have progressed through so far 5 .
• During EAMS, the product is not reimbursed, and the manufacturer is required to provide the product for free Price is negotiated (after EAMS)
NOT reimbursed (during EAMS)
The product is provided for free by the manufacturer
